Epidemiological and clinical profile of immunosuppressed patients with imported strongyloidiasis: a substudy from a larger cohort of the +REDIVI Spanish Collaborative Network.

ABSTRACT The aim of this study was to describe the clinical and epidemiological profile of immunosuppressed patients with imported strongyloidiasis in a non-endemic setting, and to compare these results with non-immunosuppressed patients. This is a case-control substudy from a larger observational retrospective study that included all patients with strongyloidiasis registered in the +REDIVI Spanish Collaborative Network. Overall, 1245 patients with imported strongyloidiasis were included. From these, 80 (6.4%) patients had some kind of immunosuppression. Three (3.8%) patients had a hyperinfection syndrome, and 34 (52.3%) patients had eosinophilia. The percentages of positive results of the formalin-ether technique, the fecal culture and serology were 12.3%, 21.1% and 95.4%, respectively. When comparing the main characteristics, immunosuppressed patients had higher proportion of severe clinical manifestations and lower proportion of eosinophilia. No differences were found regarding yield of microbiological techniques and treatment response. These results stress the importance of strongyloidiasis screening among immunosuppressed patients coming from endemic areas. Serological tests have an acceptable sensitivity to be used as a screening tool.

[1]  R. López-Vélez,et al.  Imported strongyloidiasis: Data from 1245 cases registered in the +REDIVI Spanish Collaborative Network (2009-2017) , 2019, PLoS neglected tropical diseases.

[2]  Sinuon Muth,et al.  Strongyloides stercoralis is associated with significant morbidity in rural Cambodia, including stunting in children , 2017, PLoS neglected tropical diseases.

[3]  R. López-Vélez,et al.  [Diagnosis and treatment of imported eosinophilia in travellers and immigrants: Recommendations of the Spanish Society of Tropical Medicine and International Health (SEMTSI)]. , 2017, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.

[4]  M. Viney,et al.  The biology of Strongyloides spp. , 2015, WormBook : the online review of C. elegans biology.

[5]  J. Saugar,et al.  Usefulness of Strongyloides stercoralis serology in the management of patients with eosinophilia. , 2014, The American journal of tropical medicine and hygiene.

[6]  F. Gobbi,et al.  Severe strongyloidiasis: a systematic review of case reports , 2013, BMC Infectious Diseases.

[7]  J. Llenas-García,et al.  Should We Look for Strongyloides Stercoralis in Foreign-Born HIV-Infected Persons? , 2013, Journal of Immigrant and Minority Health.

[8]  M. Siegel,et al.  Is Human Immunodeficiency Virus Infection a Risk Factor for Strongyloides stercoralis Hyperinfection and Dissemination , 2012, PLoS neglected tropical diseases.

[9]  T. Nutman,et al.  Strongyloides stercoralis in the Immunocompromised Population , 2004, Clinical Microbiology Reviews.

[10]  M. Capron,et al.  Relationship Between Interleukin‐5 Production and Variations in Eosinophil Counts During HIV Infection in West Africa: Influence of Mycobacterium tuberculosis Infection , 1999, Scandinavian journal of immunology.

[11]  S. M. Yousef,et al.  Efficacy of ELISA in diagnosis of strongyloidiasis among the immune-compromised patients. , 1995, Journal of the Egyptian Society of Parasitology.